November 28, 2016 – CHICAGO–(BUSINESS WIRE)–NTT DATA Services, formerly Dell Services, today announced its partnership with Imbio, which will provide algorithms for lung analytics. The algorithms are designed to further enhance automated tools for assisting radiology in identifying and quantifying disease present in existing and new imaging studies. The algorithms from Imbio provide for fully-automated quantification and visualization of lung structure, which is key to personalized diagnosis, surgical planning and therapy response monitoring. The Unified Clinical Archive (UCA) services from NTT DATA Services include a universal imaging analytics solution that supports machine vision and neural networks to more rapidly identify the extent of disease and accelerate the identification of incidental findings for early detection of potential chronic disease.
Pharmacy Executive Joins OneOme
MINNEAPOLIS (Nov. 30, 2016) – Pharmacogenomics company OneOme announced the addition of Harlan Langstraat, R.Ph., to its growing organization. Langstraat has joined OneOme to assist in business development activities.
Langstraat’s career has included senior management positions in both for-profit and not-for-profit healthcare organizations. Most recently, Langstraat managed the outpatient pharmacies, specialty pharmacy, mail-service pharmacy and retail medical supply businesses at Mayo Clinic, in Rochester, Minnesota. He spent fifteen years at Mayo Clinic before retiring in December 2014.
Pharmacogenomics Company OneOme Achieves Key Milestones
MINNEAPOLIS (Nov. 14, 2016) – Pharmacogenomics company OneOme today announced it has reached several milestones in the start-up organization’s development. Among the key progress indicators are $4.75 million in financing, establishment of its Minneapolis laboratory and accreditation by the College of American Pathologists (CAP), expanded sales staff and provider partnerships, and advancements in the integration of its RightMed™ test results into common EMR (electronic medical records) systems.
Pharmacogenomics Company, OneOme, Receives CAP Accreditation
MINNEAPOLIS (Oct. 31, 2016) – Twin Cities-based pharmacogenomics company OneOme announced today that the College of American Pathologists (CAP) has awarded accreditation to its Minneapolis, Minnesota, clinical laboratory based on the results of a recent on-site inspection.
Considered the “gold standard,” CAP accreditation is awarded to laboratory facilities that meet or exceed the quality standards set by the Clinical Laboratory Improvement Amendments (CLIA).
OneOme Named Finalist for 17th Annual Tekne Awards
MINNEAPOLIS (Oct. 3, 2016) – The Minnesota High Tech Association (MHTA) has named OneOme as a finalist in the Healthcare – Small and Growing category for the 2016 Tekne Awards, which will be held at the Minneapolis Convention Center on Wednesday, Nov. 16. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership.
Pharmacogenomic Company, OneOme, To Present at 2016 Annual Meeting of The American Society of Human Genetics (ASHG)
OneOme Adds Centra Health as Partner and Provider of RightMed Pharmacogenomic Test
MINNEAPOLIS (Sept. 29, 2016) – Driven to improve patient care and reduce overall healthcare costs, Twin Cities-based pharmacogenomics company OneOme continues to grow its global network and availability of the RightMed™ test with the announcement of a new partnership with Centra Health. Centra’s Stroobants Cardiovascular Center in Lynchburg, VA, joins OneOme’s growing team of provider partners.
OneOme Announces Availability of RightMed Pharmacogenomic Test
Minneapolis, Minn., July 19, 2016 – Driven to improve patient care and reduce overall healthcare costs, pharmacogenomics company OneOme announces the global availability of its RightMed™ test.
The RightMed test is a cost-effective, comprehensive pharmacogenomic analysis of 22 genes provided as a part of routine clinical care. The test helps healthcare providers easily make timely, evidenced-based, personalized prescription treatment decisions across more than 340 medications.
Pharmacogenomics Company OneOme Moves Steps Closer to Product Launch
Minneapolis, Minn., July 12, 2016 – In preparation for its full launch of the RightMed™ pharmacogenomic test, OneOme announces Paul Owen as Chief Executive Officer and opens its new headquarters and lab in northeast Minneapolis. By mid-July, OneOme will make the RightMed test commercially available to healthcare providers worldwide through www.oneome.com.
Flywheel Releases Latest Version of Data Management and Analysis Software, Exhibits at Organization for Human Brain Mapping's 2016 Annual Meeting
Pharmacogenomics Company OneOme Achieves More Key Milestones
Minneapolis, Minn., June 20, 2016 – Pharmacogenomics company OneOme is pleased to announce key business milestones in advance of launching its RightMed™ test.
The RightMed test is a cost-effective, comprehensive, personalized pharmacogenomic analysis of 22 genes provided at the point of care. The test helps providers easily make personalized treatment decisions across more than 300 medications for more than 20 medical indications.
Imbio and GE Healthcare Collaborate to Enable Lung Density Analysis Within GE Health Cloud Ecosystem
MINNEAPOLIS, March 21, 2016 /PRNewswire/ — Imbio, a leader in fully automated, biomarker-based solutions for quantitative Lung imaging, and GE Healthcare are pleased to announce a collaboration to make Imbio’s Lung Density Analysis™, a volumetric imaging solution for Lung CT, one of the first software applications to be available in the GE Health Cloud.
Flywheel and The Wandell Lab at Stanford University Enter Co-Development Agreement
MINNEAPOLIS, March 17, 2016 /PR Newswire/ – Flywheel, a scientific research software development company, announced that it has entered an agreement with Stanford University’s Vision Imaging Science and Technology (VISTA) Lab, led by Professor Brian Wandell, to further enhance the Flywheel research platform.
OneOme Expands Leadership Team in Preparation for Mid-Year Launch of its Comprehensive Pharmacogenomic Test
MINNEAPOLIS, March 17, 2016 /PRNewswire/ —OneOme, LLC, a pharmacogenomics company, announced today the hiring of Dr. Justin Odegaard, M.D., Ph.D. and Ross Higgins to manage and lead their pharmacogenomics testing laboratory. Both Dr. Odegaard and Mr. Higgins bring extensive background in laboratory medicine and clinical practice to the OneOme team in preparation for launching the OneOme RightMed™ pharmacogenomics test of 23 genes covering more than 250 medications across a spectrum of therapeutic areas.
Invenshure Opens Office in Boston, MA for Expanded Business Development Opportunities
MINNEAPOLIS, Jan. 20, 2016 – Venture catalyst Invenshure announces the establishment of its new office location in Boston, Massachusetts. This new location will function as a strategic business development office, which will allow Invenshure to develop partnerships and to research new technologies and industries on the East Coast.
OneOme Prepares for Commercial Launch in New State-of-the-Art Facility
Minneapolis, Dec. 21, 2015 /PRNewswire/— OneOme, LLC, a pharmacogenomics company, announced today that it will move its corporate office and clinical laboratory to the Highlight Center in northeast Minneapolis in early 2016. The new location will expand OneOme’s operations with a high-throughput clinical laboratory, a dedicated client service area, and an open-office layout to support the growing organization.
Flywheel Successfully Ends Private Beta Phase; Opens Platform Availability to Public
MINNEAPOLIS, MN – December 15, 2015 – Flywheel, a scientific data management company, announced that it has successfully completed its private beta phase and will offer its platform publicly to scientific researchers and institutions starting January 2016.
During the private beta phase, Flywheel installed its software at the University of Minnesota’s Center for Magnetic Resonance Research and received invaluable feedback from fMRI researchers there. Flywheel is in the process of implementing that feedback to provide the most intuitive, user-friendly, and effective product possible, so that when released to the public, the product is well-tested and ready to support the broader imaging research communities of the U.S. and of the world.
Invenshure Leads Evidentia in $1.2 Million Series A Round
MINNEAPOLIS, Minn. – Venture catalyst Invenshure announces the adoption of Evidentia Health, Inc., a company that develops innovative Enhanced Diagnostic Reports for radiology, pathology, and other specialties.
The partnership provides capital and resources to further develop Evidentia’s technology, bringing patients and referring physicians context-relevant patient education, evidence-based research and novel communication tools embedded directly in personalized reports.
Imbio Named Finalist for 16th Annual Tekne Awards
MINNEAPOLIS, Minnesota – The Minnesota High Tech Association (MHTA) has named Imbio as a finalist in the Healthcare – Small & Growing category for the 2015 Tekne Awards, which will be held at the Minneapolis Convention Center on Thursday, Nov. 18. The Tekne Awards honor Minnesota companies and individuals who have shown superior technology innovation and leadership.
